uniQure (NASDAQ:QURE) Trading Down 4.2% - Here's Why

Shares of uniQure (NASDAQ:QURE - Get Free Report) traded down 4.2% during trading on Thursday . The company traded as low as $12.99 and last traded at $13.08. 453,645 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 1,015,442 shares. The stock had previously closed at $13.65.Wall Street Analyst Weigh InA number of equities analysts have recently issued reports on QURE shares. StockNews.com upgraded uniQure to a "sell" rating in a research note on Tuesday, March 11th. Guggenheim reaffirmed a "buy" rating on shares of uniQure in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an "outperform" rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Raymond James upgraded shares of uniQure from an "outperform" rating to a "strong-buy" rating and boosted their target price for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. Finally, The Goldman Sachs Group increased their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a "neutral" rating in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $38.89.Get Our Latest Stock Analysis on uniQureuniQure Price PerformanceThe company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market cap of $673.20 million, a P/E ratio of -2.50 and a beta of 0.36. The firm's fifty day moving average is $13.82 and its two-hundred day moving average is $10.69. Insider Buying and Selling at uniQureIn other news, CEO Matthew C. Kapusta sold 28,341 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now directly owns 651,454 shares of the company's stock, valued at $6,703,461.66. This represents a 4.17 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company's stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 in the last three months. 4.74% of the stock is currently owned by corporate insiders. Hedge Funds Weigh In On uniQureInstitutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC purchased a new position in uniQure during the fourth quarter worth $38,410,000. Franklin Resources Inc. grew its holdings in uniQure by 33.1% during the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after purchasing an additional 494,726 shares during the last quarter. Point72 Asset Management L.P. raised its position in uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company's stock worth $31,282,000 after purchasing an additional 794,459 shares during the period. Integral Health Asset Management LLC lifted its stake in uniQure by 175.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock worth $19,426,000 after purchasing an additional 700,000 shares during the last quarter. Finally, RTW Investments LP boosted its position in shares of uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after buying an additional 893,625 shares during the period. Institutional investors own 78.83% of the company's stock. uniQure Company Profile (Get Free Report)uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.Recommended StoriesFive stocks we like better than uniQureHow to Invest in the FAANG StocksPenny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell What is the Euro STOXX 50 Index?Top 3 Beverage Stocks Pouring Out ProfitsStock Splits, Do They Really Impact Investors?CarMax and Carvana: Steering the Used Car MarketThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in uniQure Right Now?Before you consider uniQure, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here